Uses of Lurbinectedin

Lurbinectedin is an anti-cancer drug due to alkylation. The drug is given into the patient's body through an intravenous line. Therefore, the patient should strictly follow the treatment regimen prescribed by the doctor.

Lurbinectedin is an intravenous drug. Each patient will be prescribed a different dose depending on their body weight. Before taking the drug, the patient may be given an antiemetic to ensure safety.
Patients need to provide the treating doctor with information about the medications they are taking to make sure they do not affect the course of taking Lurbinectedin.
Drug concentration in the blood can be affected by some drugs and foods such as grapefruit, grapefruit juice, Verapamil, Ketoconazole, Rifampin, Phenytoin,... Therefore, during treatment with Lurbinectedin, people sick should not use them.

Taking the drug Lurbinectedin can cause many side effects for users as follows:
Lurbinectedin reduces the number of white blood cells or neutrophils: When taking the drug, the patient may have a decrease in the number of white blood cells, causing a decrease in the number of white blood cells. higher risk of infection. In case of symptoms such as fever, chills, sore throat, difficulty breathing, cough, burning when urinating or pain that does not heal, the patient should immediately notify the treating doctor or nurse. The drug can cause fatigue after use: Fatigue is a typical side effect after taking the drug. During cancer treatment and for some time after treatment, patients need to adjust their schedules to manage fatigue. Patients can schedule rest periods during the day and save energy for more important activities. Decreased red blood cell count (anemia): Red blood cells are the cells responsible for delivering oxygen to the body's cells. When the red blood cell count drops, the body feels fatigued. Patients should notify the doctor when feeling chest pain or difficulty breathing. In case the red blood cell count is too low, the patient may be prescribed a blood transfusion. Medicines that affect the kidneys: Lurbinectedin can cause kidney problems, including increased creatinine levels. When signs such as decreased urine output, blood in the urine, swelling of the ankles or loss of appetite appear, the patient should immediately contact a doctor for instructions. Lurbinectedin causes liver toxicity: The drug causes liver toxicity, patients appear symptoms such as jaundice, yellow eyes, yellow urine, abdominal pain. The best measure is to check liver function tests regularly. Medicines that raise blood sugar: Lurbinectedin may increase blood sugar in both patients with or without diabetes. If you notice increased thirst, urination or hunger, blurred vision, headache, fruity breath, the patient should immediately notify the treating doctor. Drugs that cause a decrease in the number of platelets: Platelets participate in the process of blood clotting. When the body appears bruises or excessive bleeding such as nosebleeds, bleeding gums, blood in urine or stools, the patient should immediately contact a doctor. Patients may have nausea or vomiting after using Lurbinectedin: Patients can take anti-emetics and change their diet accordingly. Reduce appetite or change taste: Eat foods that make the patient feel good, combine foods to increase the flavor of the food, stimulate the patient to eat better. Sensation of pain, muscle or joint pain: Use pain relievers. In addition, patients may experience constipation, shortness of breath, cough, electrolyte abnormalities, diarrhea,... Less common side effects caused by Lurbinectedin include:
Rhabdomyolysis: When tissue Damaged muscles release proteins and electrolytes into the bloodstream causing pain and muscle weakness. Extravasation causes burning sensation and pain.

Drugs can cause birth defects. Therefore, pregnant women should not take the drug to ensure the safety of the fetus. Birth control is required while taking this medication. When planning to have children, for women need to stop treatment for at least 6 months, for men need to stop treatment for at least 4 months. For women who are breast-feeding, the drug should not be taken, or should not be breast-feeding while taking it, or for 2 weeks after the last dose. Lurbinectedin's main use is to treat cancer patients. The drug is given into the patient's body through an intravenous line. This is a prescription drug, patients need to strictly follow the treatment regimen of the specialist to achieve the best treatment effect.